预约演示

更新于：2025-08-29

Naltrexone

纳曲酮

更新于：2025-08-29

概要

基本信息

简介纳曲酮是一种阿片受体拮抗剂，常用于治疗酒精和药物依赖症。VIVITROL是含有纳曲酮的药物，适用于在门诊环境下能够戒酒的酒精依赖症患者。在使用VIVITROL前，患者不应饮酒。此外，VIVITROL也适用于戒除阿片类药物后预防复发。使用VIVITROL时应该搭配心理社会支持一起实施。纳曲酮的作用机制为拮抗阿片受体中的μ、κ和δ受体。

药物类型

小分子化药

别名

DBR-LDN、Naltrexone implant、naltrexone implant(Drug Delivery Company)

+ [11]

靶点

Opioid receptors

作用方式

拮抗剂

作用机制

Opioid receptors拮抗剂(阿片样受体拮抗剂)

治疗领域

其他疾病消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

鸦片依赖酗酒甲基苯丙胺滥用+ [11]

非在研适应症

获得性免疫缺陷综合征肢端雀斑恶性黑色素瘤酒精相关疾病+ [32]

原研机构

Alkermes, Inc.

在研机构

Yale University

Neurelis, Inc.

University of California, Los Angeles

+ [11]

非在研机构

The New York State Psychiatric Institute

Dana-Farber Cancer Institute, Inc.Hershey Medical Center

+ [12]

权益机构

Statera Biopharma, Inc.

Aardvark Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

+ [9]

最高研发阶段批准上市

首次获批日期

美国 (2006-04-13),

酗酒

最高研发阶段(中国)终止

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C20H23NO4

InChIKeyDQCKKXVULJGBQN-XFWGSAIBSA-N

CAS号16590-41-3

关联

161

项与纳曲酮相关的临床试验

NCT07064564

/ Not yet recruiting临床1期

A Randomized, Comparator-Controlled, Multiple Dose-Level Study Evaluating the Pharmacokinetics and Safety of BIOPIN (Naltrexone) Implants Compared to Monthly Vivitrol Injections in Healthy Adults Over a 12-Month Period

This is a Phase 1b clinical study testing a new extended-release implant that delivers naltrexone, a medication used to treat opioid use disorder (OUD). The investigational product is called BIOPIN. It is a small implant that is inserted just under the skin of the thigh and slowly releases medication over many months. The goal of the study is to see what the blood levels of naltrexone are from two different doses of the BIOPIN implant over time and to compare it to blood levels of naltrexone from Vivitrol®, an FDA-approved injectable form of extended-release naltrexone given once a month.
This study will enroll healthy adults between the ages of 18 and 55. Participants will be randomly assigned to receive either a low dose BIOPIN implant, a high dose BIOPIN implant, or monthly Vivitrol injections. All participants will be followed closely for 12 months to monitor medication levels in their blood and assess for any side effects or health changes. The study will help determine if the BIOPIN implant can deliver naltrexone levels that are equal to or higher than those seen with monthly Vivitrol injections, particularly during the times when patients are most vulnerable to relapse.
Participants receiving the BIOPIN implant will have the option of having the implant removed at the end of the study or choosing to continue being observed until the implant fully dissolves, which may take up to two years. Participants who choose extended follow-up will be enrolled in a separate observational study.
This study is sponsored by Drug Delivery Company, LLC, with support from the National Institute on Drug Abuse (NIDA). The clinical research is being overseen by Fast-Track Research, Inc. and reviewed by Advarra IRB. All participants will undergo screening exams to ensure they are healthy and eligible, and they will be closely monitored throughout the study.
The results of this study will help researchers determine the best dose of BIOPIN to move forward into later-stage clinical trials and may support further development of long-acting treatments for opioid use disorder that do not require monthly injections or surgical removal.

开始日期2026-02-01

申办/合作机构

Drug Delivery Co. LLC

[+3]

NCT06845124

/ Not yet recruiting临床2期IIT

ICONICplus - Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence

Alcohol addiction (AD) is a chronic relapsing disorder with currently limited pharmacological treatment options. Alcohol craving, a hallmark symptom of AD that drives relapse in patients, is only insufficiently treated by existing medication. One promising new compound for the treatment of alcohol craving in AD is Cannabidiol (CBD), which showed beneficial effects on alcohol craving in preliminary clinical studies. Additionally, CBD seems to be a particularly promising candidate for enhancing the effects of established medication, specifically Naltrexone (NTX), an opioid-antagonist, which is approved for AD treatment, due to the synergistic effects of the combination of Cannabidiol plus Naltrexone on alcohol consumption that were shown by preclinical studies. The proposed three-armed, 1:1:1 randomized, double-blind, placebo-controlled parallel group, multicentric phase II trial seeks to test the putative synergistic effects of combined CBD (800mg) + oral NTX (50mg) against CBD (1200mg) + oral NTX (50mg) against Placebo + oral NTX (50mg) on alcohol craving (primary outcome) in male and female patients with AD that suffer from high alcohol craving. The trial seeks to test the effects of the innovative combination of CBD plus NTX against Placebo plus NTX on alcohol craving over a 14-day treatment period, which is embedded in a standardized addiction treatment program according to current treatment guidelines, in order to estimate the added value of treatment with CBD on alcohol craving. Quality of life and neurobiological and biochemical markers for craving will serve as secondary outcomes, because they show strong associations to treatment outcome and relapse risk. Collection and analysis of follow-up data (28 days, 42 days, 105 days, 196 days) will be performed to determine whether treatment effects relate to patient outcome.

开始日期2025-07-01

申办/合作机构

Zentralinstitut für Seelische Gesundheit

[+2]

NCT06633900

/ Recruiting临床2/3期IIT

Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV

The goal of this clinical trial is to see if an injectable medicine called naltrexone can prevent fentanyl overdose deaths in people who use other drugs (cocaine, methamphetamine). The main questions it aims to answer are:
What are the challenges for implementing naltrexone as an overdose prevention strategy?
Are injections of naltrexone effective for opioid overdose prevention among people who use stimulants?
How often are people who use stimulants and do not intentionally use opioids unintentionally exposed to opioids?
Researchers will compare participants to receive the study medication to the usual care group to see if one group experiences fewer opioid overdose events than the other.
Participants will be randomized to either receive a monthly injection of naltrexone over six months, or receive usual care. Usual care includes harm reduction supplies. Laboratory procedures will include the collection of urine, blood, and hair samples for various safety and outcome measure testing.

开始日期2025-04-10

申办/合作机构

The University of California, San Francisco

[+1]

100 项与纳曲酮相关的临床结果

登录后查看更多信息

100 项与纳曲酮相关的转化医学

登录后查看更多信息

100 项与纳曲酮相关的专利（医药）

登录后查看更多信息

9,408

项与纳曲酮相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients

Review

作者: Sheng, Nan ; Wu, Jianbing ; Fang, Fang ; Duan, Zhimin ; Li, Chengrang ; Xu, Beilei ; Song, Hao ; Zheng, Junyou

BACKGROUND:

Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

OBJECTIVE:

To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

METHODS:

Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

RESULTS:

Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

CONCLUSION:

Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

2025-12-01·Current Pain and Headache Reports

Low Dose Naltrexone In The Management Of Chronic Pain Syndrome: A Meta-Analysis Of Randomized Controlled Clinical Trials

Article

作者: Srinivasan, Anand ; V, Divya ; Hegde, Naveen Chandrashekar ; Hota, Debasish ; Mishra, Archana ; Maiti, Rituparna

OBJECTIVE:

Chronic pain conditions are among the leading causes of years lost to disability. Low Dose Naltrexone (LDN) has anti-inflammatory and immunomodulatory properties. LDN, by blocking Toll-Like Receptors (TLR), prevents central sensitization and conversion of acute pain state to a state of chronic pain. This meta-analysis compared LDN's effectiveness in chronic pain syndromes based on published randomized trials.

METHOD:

Seven studies were included after a systematic search and screening from PubMed, Embase, Scopus, Cochrane, and clinical trial registries. The efficacy outcome analyzed was the standardized mean difference (SMD), the Cohen's d, of change in pain scores between LDN and the comparator drugs using the random-effect model. Subgroup analyses by condition type and comparator were performed to analyze the effect of LDN. Adverse events were evaluated using incidence rate ratio(IRR), publication bias by funnel plot, risk of bias by Cochrane Risk of Bias tool version 2.0, and certainty of evidence by GRADE evaluation.

RESULTS:

LDN did not show a significant difference in pain response compared to control groups [d = -0.11 (95%CI -0.96 to 0.74); P = 0.31]. In fibromyalgia, LDN had improvement compared to placebo [d = -0.34 (95%CI -0.62 to -0.06); P = 0.0186]. Against active comparators, LDN had no difference [d = 0.67 (95% CI -4.69 to 6.02); P = 0.35]. Adverse events were increased with LDN compared to placebo [IRR = 1.4 (95% CI 1.12 to 1.75); P = 0.0026] but comparable to active comparators [IRR = 0.55 (95% CI 0.04 to 7.31); P = 0.65].

CONCLUSION:

LDN is better than placebo in fibromyalgia pain management, and LDN is similar to active controls in chronic pain management.

PROSPERO REGISTRATION NUMBER:

CRD42024511451.

2025-11-01·NEUROPHARMACOLOGY

Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption

Article

作者: Wolf, Kayla J ; Pressley, Justin M ; Fantegrossi, William E ; Moran, Jeffery H ; Gannon, Brenda M ; Shaw, Hannah E ; Shepard, Mary E ; Avram, Marina

Oral use of illicit fentanyl formulations is common, and these preparations may be contaminated with fentanyl analogs (FAs) with unknown pharmacological and toxicological properties. Route of administration impacts pharmacological effects, and pharmacokinetic or pharmacodynamic properties of oral fentanyl and FAs could influence aspects of opioid use disorder that are not necessarily present in animal models involving other routes of administration. We established oral consumption of water, or solutions of the FAs furanyl fentanyl and acryl fentanyl in C57 B l/6N mice. Consumption of pharmacologically-relevant concentrations of the FAs was reliably engendered, verified by induction of opioid-mediated antinociceptive effects in a warm-water tail withdrawal procedure, hypothermic effects, and observation of antagonist-precipitated withdrawal. When maintenance solutions were adulterated with the bitter tastant quinine, water control mice decreased their consumption, but mice consuming FA solutions defended their consumption, even at quinine concentrations that suppressed water drinking. Brief access to supplemental water, injection of the μ-opioid antagonist naltrexone, or administration of the μ-opioid agonist morphine all attenuated the defense of FA consumption. In all cases, the abuse-related effects of acryl fentanyl were greater than those of furanyl fentanyl. Consumption of acryl fentanyl also abolished weight gain across the study, and disrupted nest-building. The results of these experiments suggest that mice drinking furanyl fentanyl or acryl fentanyl experience opioid-mediated effects including antinociception, dependence and withdrawal, and abuse-related subjective effects, and provide proof of concept for use of this model to assess pharmacological and non-pharmacological manipulations which may attenuate the reinforcing effects of oral fentanyl and FAs.

324

项与纳曲酮相关的新闻（医药）

2025-08-26

·国际糖尿病idiabetes

ESC肥胖与心血管疾病临床共识声明：十大要点一文汇总

点击“蓝字”关注我们编者按：全球肥胖的患病率在过去四十年中翻了一倍多，目前有10亿人受累。肥胖不仅是众多慢病的高危因素，其本身也被定义为一种疾病，显著降低生活质量与寿命。尽管肥胖与动脉粥样硬化、心力衰竭、血栓栓塞性疾病、心律失常及猝死等密切相关，但受重视程度却远不及其他可干预危险因素。欧洲心脏病学会（ESC）发布的《肥胖与心血管疾病临床共识声明》基于最新循证，系统阐述了肥胖的流行病学、病因及与心血管风险交互作用，并就生活方式、内镜/外科及药物减重策略提出管理路径，旨在将肥胖纳入心血管一级与二级预防的核心环节。欧洲心脏病学会（ESC）关于肥胖与心血管疾病（CVD）的临床共识声明讨论了肥胖、心血管危险因素和CVD之间的相互作用，并为心脏病和肥胖患者的临床管理提供了指导，特别关注减重策略对心脏代谢风险和心血管结局的影响（图1）。共识指出，肥胖不仅与多种CVD的发生相关，还与死亡风险，尤其是心血管死亡风险增加相关。以下为声明的十大要点。图1. （A）肥胖的主要心血管结局，（B）各种干预措施对体重的平均影响 01 肥胖流行形势严峻全球范围内，肥胖的患病率在过去数十年中已翻了一倍以上。在ESC成员国中，约五分之一的成年人患有肥胖，全球范围内这一比例约为八分之一。 02 肥胖评估需综合多项指标目前，肥胖诊断和分类的金标准仍是基于体重指数（BMI）。然而，BMI无法反映肌肉质量与体脂含量及分布。因此，结合腹部肥胖指标，如腰围、腰高比和腰臀比，有助于在BMI基础上进一步优化个体的心血管代谢风险分层。 03 肥胖病因复杂，受多因素影响肥胖的病因具有高度复杂性和多因素性。尽管遗传与生物学因素在个体易感性中发挥重要作用，但全球肥胖流行主要由环境与社会因素驱动。 04 生活方式干预是基础生活方式干预是体重管理的基础。饮食干预通常建议每日实现500~750 kcal的能量负平衡，可实现5%~10%的体重下降。体力活动对体重减轻的直接作用相对有限，但在维持减重成果和降低总体心血管风险方面至关重要。尽管结合营养与运动的强化生活方式干预可改善心血管代谢危险因素，但对心血管结局的影响尚未在随机对照试验中得到证实。 05 药物干预显示新希望在药物干预方面，奥利司他和安非他酮/纳曲酮对体重的影响有限，长期心血管安全性证据不足。胰高糖素样肽-1受体激动剂（GLP-1RA）可有效减重并改善心血管危险因素。司美格鲁肽（2.4 mg，每周一次）在合并CVD且超重或肥胖（BMI≥27 kg/m2）但无糖尿病的患者中，显示出明确的心血管获益。 06 胃内介入与手术干预效果显著内镜下干预（如胃内球囊、内镜下袖状胃成形术）可实现7%~13%的体重下降，减重代谢手术可达25%~30%。这些干预措施适用于经过严格筛选的个体。观察性研究表明，减重手术与心血管结局改善相关，但目前尚缺乏随机对照试验数据。 07 减重是控制合并症的基石肥胖几乎对所有可干预的心血管危险因素均可产生不利影响。对于合并2型糖尿病、高血压、血脂异常或阻塞性睡眠呼吸暂停的肥胖患者，减重是治疗的基石。 08 肥胖显著增加心力衰竭风险肥胖显著增加新发心力衰竭的风险，尤其是射血分数保留的心力衰竭（HFpEF）。通过饮食、运动或药物干预减重，可改善肥胖HFpEF患者的运动能力和临床症状。对于合并射血分数降低的心力衰竭（HFrEF）的肥胖患者，生活方式干预减重可能改善症状和运动能力，但非意愿性体重下降则与死亡风险升高相关。 09 肥胖与房颤风险密切相关肥胖者发生房颤及进展为永久性房颤的风险更高，且血栓栓塞风险也增加。对于肥胖个体，应鼓励减重以进行房颤的一级预防。对于已确诊房颤的肥胖患者，减重结合其他危险因素管理，有助于降低房颤相关症状负担。 10 肥胖治疗需兼顾成本效益与可及性对部分CVD患者而言，个体化的肥胖治疗可能具有成本效益，但目前因个人和社会经济负担，多数患者仍难以获得有效治疗。从医学和成本效益的角度来看，预防才是应对肥胖流行的最优策略，应从儿童期开始推动终身健康体重维持，并在政策层面实施多维度干预，以抵消当前“致肥胖环境”的影响。参考文献：Koskinas KC, Van Craenenbroeck EM, Prescott EB. European Society of Cardiology clinical consensus statement on obesity and cardiovascular disease: 10 key points. Eur Heart J. 2025 Aug 21:ehaf177. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《心肾代谢时讯》编辑部）

AHA会议

2025-08-25

·奇点网

《自然·医学》：氯胺酮抗抑郁机制新突破！科学家发现，氯胺酮的抗抑郁作用需要阿片系统介导

*仅供医学专业人士阅读参考在过去十年中，氯胺酮作为一种快速起效的抗抑郁药物引起了广泛关注。尽管机制还不是十分明确，但有研究指出，氯胺酮能通过阻断GABA能中间神经元，诱发谷氨酸释放，从而激活AMPA受体并促进突触可塑性，实现快速缓解抑郁症状的效果。然而，氯胺酮的作用机制远不止于谷氨酸系统。越来越多的研究表明，阿片类系统，尤其是μ阿片受体（MOR），可能在氯胺酮的抗抑郁效应中发挥关键调节作用。临床前研究显示，阻断阿片受体会显著削弱氯胺酮的抗抑郁效果，但这些研究样本量较小，且未能明确揭示其背后的神经机制。为此，英国伦敦国王学院的研究团队在重度抑郁症患者中开展了一项随机双盲交叉临床试验，结合功能性磁共振波谱技术，他们发现，阿片受体拮抗剂纳曲酮会削减氯胺酮引起的谷氨酸活动的增加，并削弱其抗抑郁效果。这一结果揭示了氯胺酮的抗抑郁作用不仅依赖于谷氨酸系统，还可能需要阿片系统的协同激活。谷氨酸和阿片类系统之间的相互作用可能会对抑郁症的治疗策略的开发产生新的启示。研究结果发表在了《自然·医学》杂志上[1]。这项临床试验纳入了28名重度抑郁症患者，被随机分为两组，每名受试者交叉接受两次治疗，分别是口服安慰剂+静脉注射氯胺酮、口服纳曲酮+静脉注射氯胺酮，两次之间的时间间隔为14-33天。共有25名受试者完成了两次治疗。研究人员使用蒙哥马利抑郁评定量表（MADRS）评估受试者的抑郁症状，以及受试者自报告的抑郁症状快速自评量表（QIDS-SR）和莫兹利三项目视觉模拟量表（M3VAS）作为辅助。此外，使用斯奈斯-汉密尔顿快感量表（SHAPS）和快感时间体验量表（TEPS，包含预测性和即时性快感体验两种）评估快感缺失症状，使用临床评定解离状态量表（CADSS）评估解离症状（如现实感丧失、人格分离等），使用拟精神病状态量表（PSI）评估类似精神病的主观感受（如幻觉、妄想等）。研究人员还使用功能性磁共振波谱（¹H-fMRS）实时监测了前扣带皮层（ACC）的谷氨酸+谷氨酰胺（Glx）水平。在安慰剂组中，氯胺酮使得受试者的MADRS评分平均下降14.65分，而纳曲酮组平均下降10.50分，纳曲酮显著削弱了氯胺酮的抗抑郁效果。自评量表QIDS-SR和M3VAS也显示出症状减轻，但纳曲酮组与安慰剂组之间差异不显著。SHAPS和TEPS量表评估的快感缺失症状显示，两组在治疗后快感缺失都有所改善，纳曲酮组改善程度较低，但未达到统计学显著性。在解离症状与类精神病的主观感受方面，两组在这些主观效应上的评分无显著差异。功能性磁共振波谱的监测结果显示，作为谷氨酸活性的标志物，谷氨酸+谷氨酰胺与N-乙酰天冬氨酸+N-乙酰天冬氨酰谷氨酸的比值（Glx/tNAA）在安慰剂组中显著增加，在注射后15-25分钟后达到峰值，而在纳曲酮组中被显著削弱，这表明，阿片系统的阻断会抑制氯胺酮引起的谷氨酸活动增加。敏感性分析显示，年龄、性别和抗抑郁药物等因素不会影响这一结果，并且在男性受试者中，组间的差异更明显。综上所述，这项研究支持了氯胺酮给药会显著提升抑郁症患者ACC中谷氨酸能活性这一假说，而阿片受体拮抗剂纳曲酮的合并给药可以削弱这种影响和氯胺酮的抗抑郁效果。研究为理解氯胺酮的多系统抗抑郁机制提供了重要线索，未来，需要进一步研究阿片系统与谷氨酸系统之间的交互作用，也提示临床医生在使用氯胺酮治疗抑郁症时，应谨慎联合使用阿片受体拮抗剂，尤其是在急性治疗阶段，并且有望推动开发兼顾谷氨酸与阿片系统的新型抗抑郁药物，实现更快速、更持久的治疗。参考文献：[1] Jelen L A, Lythgoe D J, Stone J M, et al. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study[J]. Nature Medicine, 2025: 1-9.本文作者丨应雨妍

临床结果

2025-08-14

·EINPresswire

Vegas Stronger and Clark County Detention Center Celebrate Proven Success of MAT Program in Reducing Recidivism

This is about more than medication — it’s about rebuilding lives, reducing crime, and creating safer communities.” — David Marlon LAS VEGAS, NV, UNITED STATES, August 14, 2025 / EINPresswire.com / -- Vegas Stronger, in collaboration with Las Vegas Metropolitan Police Department Detention Services Division (DSD), announced today compelling results from its Post Release Medication Assisted Treatment (MAT) Program, showing significant progress in breaking the cycle of incarceration, addiction, and homelessness. The MAT Program, launched to bridge the gap between incarceration and successful community reintegration, offers evidence-based treatment combining FDA-approved medications such as buprenorphine and naltrexone with a comprehensive suite of behavioral health and wraparound services. Participants receive in-reach engagement while still incarcerated, immediate connection to care upon release, and long-term integrated support to ensure lasting recovery. Since its inception, the program has: • Served 74 individuals referred through CCDC, with 51 clients admitted and an active engagement rate of 62.7%. • Provided a total of 2,475 days in treatment, with an average length of stay of 48.5 days per participant — a figure expected to increase as the program matures. • Achieved preliminary research outcomes showing 88% of program graduates remain clean and sober after six months, and 77% sustain sobriety after twelve months. “By fostering trust inside the detention center before release, and ensuring a warm hand-off into treatment, we’re seeing transformational results,” said David Marlon, Co-Founder and CEO of Vegas Stronger. “This is about more than medication — it’s about rebuilding lives, reducing crime, and creating safer communities.” The MAT Program operates under the Vegas Stronger Method, a 13-element holistic model that includes medical care, counseling, peer recovery coaching, vocational training, housing assistance, fitness and nutrition programs, and community service opportunities. This integrated support system addresses not only addiction but also the underlying social determinants of health that can lead to relapse and reoffending. With early data already showing reduced emergency room visits, fewer relapses, and promising retention rates, Vegas Stronger and LVMPD DSD are committed to expanding the program and refining long-term measurements, including recidivism rates, employment outcomes, and housing stability. Media Contact: Matt Yemma Endeavor Communications 909-633-9396 Matthew@endeavorcomms.net About Vegas Stronger Vegas Stronger is a behavioral healthcare provider committed to delivering evidence-based, integrated treatment to Southern Nevada’s most underserved populations. Through a holistic approach that addresses the medical, psychological, and social needs of each individual, Vegas Stronger empowers clients to achieve long-term recovery and stability. About Las Vegas Metropolitan Police Department Detention Services Division The Las Vegas Metropolitan Police Department operates the Clark County Detention Center, providing safe, secure, and humane detention services while supporting rehabilitation and reentry programs that promote public safety and reduce recidivism. Matthew Yemma Endeavor Communications +1 909-633-9396 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果

100 项与纳曲酮相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鸦片依赖	美国	Alkermes, Inc.	2010-10-12
酗酒	美国	Alkermes, Inc.	2006-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿片类药物过量	临床3期	美国	The University of California, San Francisco	2025-04-10
甲基苯丙胺滥用	临床3期	美国	National Institute on Drug Abuse	2024-07-01
甲基苯丙胺依赖	临床3期	美国	National Institute on Drug Abuse	2024-07-01
大便失禁	临床3期	美国	Yale University	2021-06-29
慢性盆腔疼痛综合征	临床3期	美国	Hershey Medical Center	2020-01-16
子宫内膜异位症	临床3期	美国	Hershey Medical Center	2020-01-16
暴食症	临床3期	美国	Yale University	2019-08-07
肥胖	临床3期	美国	Yale University	2019-08-07
阿片滥用	临床3期	美国	Alkermes, Inc.	2016-04-01
获得性免疫缺陷综合征	临床3期	美国	Yale University	2011-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02330419 (SayWhen, CTgov)	临床2期	HIV感染	120	Behavioral survey measurements: (Placebo)	鹹艱築壓願醖顧範襯憲(觸廠構觸簾艱夢鏇鏇網) = 繭網築鏇製齋鏇淵廠艱遞顧鏇顧繭網鹹鹽選獵 (鏇觸夢艱憲艱獵膚觸鏇, 築鑰蓋繭積壓餘願窪糧 ~ 衊繭網餘齋憲繭壓醖鹽) 更多	-	2025-04-20
				Behavioral survey measurements:+Naltrexone (Naltrexone)	鹹艱築壓願醖顧範襯憲(觸廠構觸簾艱夢鏇鏇網) = 繭艱網淵憲廠淵築獵鬱遞顧鏇顧繭網鹹鹽選獵 (鏇觸夢艱憲艱獵膚觸鏇, 壓夢簾遞鬱願選壓鬱糧 ~ 齋餘衊構範壓艱襯膚壓) 更多
NCT01587196 (fMRI CURE, CTgov)	临床2期	-	72	Vivitrol	簾醖襯網淵壓艱範襯蓋 = 蓋積鹽願鹹鹹觸範鑰觸鑰餘艱壓餘夢醖獵積網 (窪鹹艱壓鏇繭遞夢糧獵, 簾窪範膚範鹹觸蓋蓋繭 ~ 鹽醖觸鬱構獵製襯鑰鹹) 更多	-	2024-10-15
NCT04547985 (PGD, CTgov)	临床4期	-	9	Placebo (Placebo)	繭簾範選壓窪選觸膚簾(衊壓齋艱築鬱觸夢餘醖) = 鹽網鏇衊鬱構鹹積窪襯鏇觸構淵艱餘夢鏇膚選 (簾觸鑰襯築網鬱壓窪鑰, 7.36) 更多	-	2024-08-28
				Naltrexone HCl 50 MG Oral Tablet (Naltrexone)	繭簾範選壓窪選觸膚簾(衊壓齋艱築鬱觸夢餘醖) = 遞餘壓齋膚獵製壓遞遞鏇觸構淵艱餘夢鏇膚選 (簾觸鑰襯築網鬱壓窪鑰, NA) 更多
DDW2024	N/A	酒精性肝疾病	-	Naltrexone	憲餘顧鏇憲構製窪選鹽(艱襯膚衊齋壓膚繭憲觸) = 鹹糧範憲襯鹽築簾積鑰製鬱構鑰遞餘鏇鏇餘簾 (壓範糧製鏇網築鹹鏇餘 )	-	2024-05-20
				Acamprosate	憲餘顧鏇憲構製窪選鹽(艱襯膚衊齋壓膚繭憲觸) = 艱觸艱醖範廠鑰膚窪築製鬱構鑰遞餘鏇鏇餘簾 (壓範糧製鏇網築鹹鏇餘 )
DDW2024	N/A	酒精性肝疾病	-	Naltrexone	鹹膚製積鹽廠衊顧壓膚(獵夢憲膚糧選觸範鑰築) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI 願願獵範糧艱範餘衊廠 (範窪簾簾醖網壓鬱糧鬱 ) 更多	-	2024-05-20
				Acamprosate
NCT02885311 (CTgov)	临床1/2期	酗酒 \| 酒精相关疾病	27	Brief Advice (At-Risk Drinkers (AR))	蓋範鏇顧糧願網憲衊範(醖憲鹽壓廠鑰衊築鏇壓) = 鹽膚齋壓鹽淵願齋衊鑰鏇網築壓膚鏇蓋鏇夢蓋 (遞網壓艱艱積夢簾顧獵, 4.1) 更多	-	2023-10-30
				Brief Advice+Naltrexone (Problem Drinkers (PD))	蓋範鏇顧糧願網憲衊範(醖憲鹽壓廠鑰衊築鏇壓) = 餘齋壓築積膚顧積繭範鏇網築壓膚鏇蓋鏇夢蓋 (遞網壓艱艱積夢簾顧獵, 8.0) 更多
NCT04249882 (CTgov)	临床2期	酒精使用障碍	53	Placebo (Placebo)	築構顧窪夢鬱願範構窪(範繭範遞簾艱鑰積壓壓) = 遞膚艱衊襯廠窪積積廠廠鏇夢糧鏇鹹鬱鑰鏇糧 (願構網製觸壓觸淵鬱獵, 6.67) 更多	-	2023-09-14
				Varenicline (Varenicline)	築構顧窪夢鬱願範構窪(範繭範遞簾艱鑰積壓壓) = 鬱衊觸範願簾艱糧襯艱廠鏇夢糧鏇鹹鬱鑰鏇糧 (願構網製觸壓觸淵鬱獵, 6.87) 更多
NCT04094584 (CTgov)	临床4期	酒精使用障碍	179	Naltrexone	廠蓋鑰範糧餘窪選襯膚 = 膚鹽選簾餘鑰艱遞網選鹽壓鏇襯鏇構糧鏇衊網 (鏇衊鏇選範齋築鑰衊構, 觸蓋醖廠夢鏇構糧製糧 ~ 繭構積構憲鑰積壓獵憲) 更多	-	2023-06-22
NCT04716881 (CTgov)	临床1期	阿片相关性障碍	9	Naltrexone 380 MG	艱襯鑰淵鹹構網積觸鹹(鹽顧齋遞積齋鹹鏇製艱) = 積糧醖顧範觸網壓構網襯醖簾夢顧鹹壓製糧製 (顧繭遞鏇鏇蓋簾鏇壓憲, 醖衊壓鬱齋襯窪醖網範 ~ 淵憲窪醖選鹽醖簾築壓) 更多	-	2023-06-09